Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial
Open-label, continuation study
Solid Tumors
DRUG: TRC105|DRUG: Bevacizumab|DRUG: Axitinib|DRUG: Pazopanib|DRUG: Capecitabine
This is a multicenter, open-label, non-randomized, study of TRC105 in patients that have completed a previous TRC105 study and are judged by the investigator to have the potential to benefit from continued TRC105 therapy.